Bolt Biotherapeutics Inc BOLT

NAS: BOLT | ISIN: US0977021049 8/07/2025

6,040 USD (+2,90%)

(+2,90%) 8/07/2025

Toon enkel gratis nieuws

31 augustus 2024 · INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt · Persbericht

21 augustus 2024 · INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt · Persbericht

14 augustus 2024 · SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt · Persbericht

7 augustus 2024 · DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt · Persbericht

31 juli 2024 · SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt · Persbericht

25 juli 2024 · DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt · Persbericht

19 juli 2024 · Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt Lawsuit · Persbericht

10 juli 2024 · SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt · Persbericht

2 juli 2024 · Pomerantz Law Firm Announces the Filing of a Class Action Against Bolt Biotherapeutics, Inc. and Certain Officers - BOLT · Persbericht

30 mei 2023 · BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe